Inspire Medical Systems, Inc. (NYSE:INSP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $219.58.

A number of equities research analysts recently commented on INSP shares. KeyCorp decreased their target price on shares of Inspire Medical Systems from $278.00 to $236.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. Robert W. Baird decreased their target price on shares of Inspire Medical Systems from $220.00 to $200.00 and set an "outperform" rating for the company in a research report on Wednesday, August 7th. Morgan Stanley decreased their target price on shares of Inspire Medical Systems from $250.00 to $210.00 and set an "overweight" rating for the company in a research report on Monday, July 15th. Leerink Partners raised their price target on shares of Inspire Medical Systems from $167.00 to $197.00 and gave the stock a "market perform" rating in a report on Tuesday, September 10th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $240.00 price target (up previously from $217.00) on shares of Inspire Medical Systems in a report on Monday, September 30th.

Inspire Medical Systems Stock Down 0.8 %

Shares of NYSE INSP traded down $1.49 during midday trading on Thursday, reaching $195.07. 394,728 shares of the company's stock traded hands, compared to its average volume of 593,418. The stock's 50 day simple moving average is $200.92 and its 200-day simple moving average is $181.13. Inspire Medical Systems has a one year low of $123.00 and a one year high of $257.40. The company has a market cap of $5.80 billion, a price-to-earnings ratio of -357.95 and a beta of 1.34.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.46. Inspire Medical Systems had a net margin of 0.85% and a return on equity of 1.03%. The firm had revenue of $195.89 million for the quarter, compared to the consensus estimate of $189.08 million. During the same period last year, the firm earned ($0.41) earnings per share. The company's quarterly revenue was up 29.6% on a year-over-year basis. Equities analysts predict that Inspire Medical Systems will post 0.75 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 800 shares of the business's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares of the company's stock, valued at $5,090,800. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Shawn Mccormick sold 800 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now owns 23,140 shares of the company's stock, valued at approximately $5,090,800. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Randy Ban sold 4,861 shares of the company's stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the sale, the insider now directly owns 3,056 shares of the company's stock, valued at approximately $576,208.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,692 shares of company stock valued at $1,099,207 over the last 90 days. Corporate insiders own 4.10% of the company's stock.

Institutional Trading of Inspire Medical Systems

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its stake in Inspire Medical Systems by 98.9% during the 1st quarter. Russell Investments Group Ltd. now owns 31,933 shares of the company's stock valued at $6,859,000 after acquiring an additional 15,877 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Inspire Medical Systems by 51.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company's stock valued at $98,754,000 after purchasing an additional 156,893 shares during the last quarter. Tidal Investments LLC acquired a new position in Inspire Medical Systems in the 1st quarter valued at about $1,151,000. AQR Capital Management LLC boosted its holdings in Inspire Medical Systems by 152.7% in the 2nd quarter. AQR Capital Management LLC now owns 231,845 shares of the company's stock valued at $31,028,000 after purchasing an additional 140,090 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in Inspire Medical Systems by 27.1% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 40,501 shares of the company's stock valued at $8,699,000 after purchasing an additional 8,625 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company's stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.